FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026
Rhea-AI Summary
FocalTherics (Nasdaq: FOCL) will release its second quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursday, August 13, 2026. The company will host a conference call and webcast at 4:30 p.m. Eastern Time, led by CEO Ryan Rhodes, CFO Ken Mobeck, and Chief Accounting Officer François Dietsch.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 30 | European program launch | Positive | +0.7% | First European commercial endometriosis program launched with initial patients treated. |
| Jun 16 | VA access agreement | Positive | +0.0% | Agreement expanded access to robotic focal therapy across federal healthcare systems. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior news events were followed by a 0.68% gain and a 0% change.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT
FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026
Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT
AUSTIN, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics (Nasdaq: FOCL) (the “Company”), the global leader in robotic focal therapy, today announced that it will release its financial results for the second quarter ended June 30, 2026, after market close on Thursday, August 13, 2026.
An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Call Details:
| Date: | Thursday, August 13, 2026, at 4:30 p.m. Eastern Time |
| Domestic: | 1-800-245-3047 |
| International: | 1-203-518-9765 |
| Passcode: | FOCAL |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1767672&tp_key=2d69d92ca7 |
About FocalTherics
A recognized global leader in Robotic Focal Therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life. FocalTherics is committed to expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and global market development initiatives. For more information about FocalTherics, visit FocalTherics.com.
Investor Contacts
Louisa Smith
Gilmartin Group
investor.relations@focalone.com
